Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Главные авторы: Qiao Liu (Автор), Zhen Zhou (Автор), Xia Luo (Автор), Lidan Yi (Автор), Liubao Peng (Автор), Xiaomin Wan (Автор), Chongqing Tan (Автор), Xiaohui Zeng (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...